Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Blood Advances|February 5, 2025
Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomasYomani D Sarathkumara, Nathan W Van Bibber, Zhiwei Liu, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
Differential EBV protein-specific antibody response between responders and non-responders to EBVSTs immunotherapyYomani D Sarathkumara, Nathan W Van Bibber, Zhiwei Liu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 5, 2018
CD7 CAR T Cells for the Therapy of Acute Myeloid LeukemiaDiogo Gomes-Silva, Erden Atilla, Pinar Ataca Atilla, et al.
Transplantation and Cellular Therapy|November 1, 2025
Opportunities and Challenges With CAR T-cell Treatment of Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations From the Westhafen Intercontinental GroupCandelaria Deimundo Roura, Persis Amrolia, Marc Ansari, et al.
Cell Reports. Medicine|July 10, 2024
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicityRoyce Ma, Mae Woods, Phillip Burkhardt, et al.
Blood Advances|November 21, 2024
American Society of Hematology: building a comprehensive minority recruitment and retention professional programMargo R Rollins, Rahma M Warsame, Melody Smith, et al.
Transplantation and Cellular Therapy|May 18, 2024
ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell TherapiesRebecca A Gardner, Claire White, Magdi Elsallab, et al.
Cytotherapy|May 31, 2024
Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumorsAnne Miller, Rachel Daum, Tao Wang, et al.
Pediatric Blood & Cancer|January 20, 2025
Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid TumorsAaron B Ross, Kriti Puri, Thomas L Johnson, et al.
Haematologica|October 20, 2022
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemiaAlan S Wayne, Van Huynh, Nobuko Hijiya, et al.
Pageof 5